target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id μ receptor,319,P35372,Human,(-)-bremazocine,1603,,443406,CC[C@]12CCN([C@@H](C2(C)C)Cc2c1cc(O)cc2)CC1(O)CC1,"InChI=1S/C20H29NO2/c1-4-20-9-10-21(13-19(23)7-8-19)17(18(20,2)3)11-14-5-6-15(22)12-16(14)20/h5-6,12,17,22-23H,4,7-11,13H2,1-3H3/t17-,20+/m1/s1",ZDXGFIXMPOUDFF-XLIONFOSSA-N,Antagonist,Antagonist,,,,,pKi,,9.7,,,,,,,,,,9686407, μ receptor,319,P35372,Human,(-)-cyclazocine,1604,,21779964,Oc1ccc2c(c1)[C@]1(C)CCN([C@@H](C2)C1C)CC1CC1,"InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3/t12?,17-,18+/m0/s1",YQYVFVRQLZMJKJ-OTLVQASYSA-N,Agonist,Partial agonist,,,,,pKi,,10.0,,,,,,,,,,9686407, μ receptor,319,P35372,Human,(-)-methadone,1605,,22267,CCC(=O)C(c1ccccc1)(c1ccccc1)C[C@H](N(C)C)C,"InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m1/s1",USSIQXCVUWKGNF-QGZVFWFLSA-N,Agonist,Full agonist,,,,,pKi,,9.2,,,,,,,,,,9686407, μ receptor,319,P35372,Human,(-)-pentazocine,1606,,441278,CC(=CCN1CC[C@@]2([C@H]([C@H]1Cc1c2cc(cc1)O)C)C)C,"InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1",VOKSWYLNZZRQPF-GDIGMMSISA-N,Agonist,Partial agonist,,,,,pKi,,8.4,,,,,,,,,,9686407, μ receptor,319,P35372,Human,DADLE,1607,,6917707,Oc1ccc(cc1)C[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)O)CC(C)C)Cc1ccccc1)C)N,"InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1",ZHUJMSMQIPIPTF-IBURTVSXSA-N,Agonist,Full agonist,,,,,pKi,,8.7,,,,,,,,,,9686407, μ receptor,319,P35372,Human,DSLET,1609,,107847,OC[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)[C@H](O)C)CC(C)C)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)N,"InChI=1S/C33H46N6O10/c1-18(2)13-24(32(47)39-28(19(3)41)33(48)49)37-31(46)25(15-20-7-5-4-6-8-20)36-27(43)16-35-30(45)26(17-40)38-29(44)23(34)14-21-9-11-22(42)12-10-21/h4-12,18-19,23-26,28,40-42H,13-17,34H2,1-3H3,(H,35,45)(H,36,43)(H,37,46)(H,38,44)(H,39,47)(H,48,49)/t19-,23+,24+,25+,26-,28+/m1/s1",PKSODCLCMBUCPW-LVNBQDLPSA-N,Agonist,Full agonist,,,,,pKi,,8.2,,,,,,,,,,9686407, μ receptor,319,P35372,Human,ethylketocyclazocine,1610,,135018,CC[C@@]12CCN([C@H]([C@H]1C)C(=O)c1c2cc(O)cc1)CC1CC1,"InChI=1S/C19H25NO2/c1-3-19-8-9-20(11-13-4-5-13)17(12(19)2)18(22)15-7-6-14(21)10-16(15)19/h6-7,10,12-13,17,21H,3-5,8-9,11H2,1-2H3/t12-,17-,19-/m1/s1",SEJUQQOPVAUETF-QHLBDZCJSA-N,Agonist,Full agonist,,,,,pKi,,9.5,,,,,,=,,,,9686407, μ receptor,319,P42866,Mouse,[3H]diprenorphine,1612,,6858272,CO[C@]12CC[C@]3(C[C@@H]1C(O)(C)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3N(C(C1[3H])[3H])CC1CC1)ccc2O,"InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1/i10T,11T/t10?,11?,18-,19-,22-,24-,25+,26-",OIJXLIIMXHRJJH-ZXJLXYCOSA-N,Antagonist,Antagonist,,,,,pKd,,10.1,,Kd,,0.0794,,=,,,,8114680, μ receptor,319,P35372,Human,[Leu]enkephalin,1613,"Human, Mouse, Rat",3903,O=C(CNC(=O)C(Cc1ccc(cc1)O)N)NCC(=O)NC(C(=O)NC(C(=O)O)CC(C)C)Cc1ccccc1,"InChI=1S/C28H37N5O7/c1-17(2)12-23(28(39)40)33-27(38)22(14-18-6-4-3-5-7-18)32-25(36)16-30-24(35)15-31-26(37)21(29)13-19-8-10-20(34)11-9-19/h3-11,17,21-23,34H,12-16,29H2,1-2H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)(H,39,40)",URLZCHNOLZSCCA-UHFFFAOYSA-N,Agonist,Partial agonist,,yes,,,pKi,,8.1,,,,,,,,,,9686407, μ receptor,319,P33535,Rat,[Met]enkephalin,1614,"Human, Mouse, Rat",443363,CSCC[C@@H](C(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(cc1)O)N,"InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1",YFGBQHOOROIVKG-FKBYEOEOSA-N,Agonist,Full agonist,,yes,,,pKi,,9.2,,,,,,,,,,8114680, μ receptor,319,P35372,Human,dihydromorphine,1616,,5359421,O[C@H]1CC[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O,"InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",IJVCSMSMFSCRME-KBQPJGBKSA-N,Agonist,Full agonist,,,,,pKi,,8.8,,,,,,,,,,9686407, μ receptor,319,P35372,Human,diprenorphine,1617,,443408,CO[C@]12CC[C@]3(C[C@@H]1C(O)(C)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3N(CC1)CC1CC1)ccc2O,"InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1",OIJXLIIMXHRJJH-KNLIIKEYSA-N,Antagonist,Antagonist,,,,,pKi,,9.1,,,,,,,,,,9686407, μ receptor,319,P42866,Mouse,diprenorphine,1617,,443408,CO[C@]12CC[C@]3(C[C@@H]1C(O)(C)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3N(CC1)CC1CC1)ccc2O,"InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1",OIJXLIIMXHRJJH-KNLIIKEYSA-N,Antagonist,Antagonist,,,,,pKi,,10.1,,,,,,,,,,8114680, μ receptor,319,P35372,Human,dynorphin-(1-11),1618,,3086114,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O,"InChI=1S/C63H103N21O13/c1-5-37(4)51(58(94)80-44(20-13-29-74-63(70)71)59(95)84-30-14-21-48(84)57(93)81-45(60(96)97)17-9-10-26-64)83-54(90)43(19-12-28-73-62(68)69)78-53(89)42(18-11-27-72-61(66)67)79-55(91)46(31-36(2)3)82-56(92)47(33-38-15-7-6-8-16-38)77-50(87)35-75-49(86)34-76-52(88)41(65)32-39-22-24-40(85)25-23-39/h6-8,15-16,22-25,36-37,41-48,51,85H,5,9-14,17-21,26-35,64-65H2,1-4H3,(H,75,86)(H,76,88)(H,77,87)(H,78,89)(H,79,91)(H,80,94)(H,81,93)(H,82,92)(H,83,90)(H,96,97)(H4,66,67,72)(H4,68,69,73)(H4,70,71,74)/t37-,41-,42-,43-,44-,45-,46-,47-,48-,51-/m0/s1",WZHQALIQGVYQGG-QFIUEGLPSA-N,Agonist,Full agonist,,,,,pKi,,8.8,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,dynorphin A-(1-13),1619,"Human, Mouse, Rat",25077992,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O,"InChI=1S/C75H126N24O15/c1-7-45(6)61(70(111)94-53(25-17-35-87-75(83)84)71(112)99-36-18-26-58(99)69(110)93-50(21-11-13-31-76)64(105)96-56(38-44(4)5)67(108)95-54(72(113)114)22-12-14-32-77)98-65(106)52(24-16-34-86-74(81)82)91-63(104)51(23-15-33-85-73(79)80)92-66(107)55(37-43(2)3)97-68(109)57(40-46-19-9-8-10-20-46)90-60(102)42-88-59(101)41-89-62(103)49(78)39-47-27-29-48(100)30-28-47/h8-10,19-20,27-30,43-45,49-58,61,100H,7,11-18,21-26,31-42,76-78H2,1-6H3,(H,88,101)(H,89,103)(H,90,102)(H,91,104)(H,92,107)(H,93,110)(H,94,111)(H,95,108)(H,96,105)(H,97,109)(H,98,106)(H,113,114)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t45-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1",OVVIBUHLQIYUEU-IWIISZHXSA-N,Agonist,Full agonist,,yes,,,pKi,,8.3,,,,,,,,,,9686407, μ receptor,319,P35372,Human,dynorphin A,1620,"Human, Mouse, Rat",16133805,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O,"InChI=1S/C99H155N31O23/c1-7-55(6)81(129-86(142)66(28-18-40-112-98(107)108)118-83(139)65(27-17-39-111-97(105)106)120-88(144)70(44-54(4)5)125-89(145)71(46-56-21-9-8-10-22-56)117-79(135)52-115-78(134)51-116-82(138)61(102)45-57-31-33-59(131)34-32-57)94(150)122-67(29-19-41-113-99(109)110)95(151)130-42-20-30-75(130)93(149)121-64(26-14-16-38-101)85(141)124-69(43-53(2)3)87(143)119-63(25-13-15-37-100)84(140)126-72(47-58-50-114-62-24-12-11-23-60(58)62)90(146)128-74(49-80(136)137)92(148)127-73(48-77(104)133)91(147)123-68(96(152)153)35-36-76(103)132/h8-12,21-24,31-34,50,53-55,61,63-75,81,114,131H,7,13-20,25-30,35-49,51-52,100-102H2,1-6H3,(H2,103,132)(H2,104,133)(H,115,134)(H,116,138)(H,117,135)(H,118,139)(H,119,143)(H,120,144)(H,121,149)(H,122,150)(H,123,147)(H,124,141)(H,125,145)(H,126,140)(H,127,148)(H,128,146)(H,129,142)(H,136,137)(H,152,153)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113)/t55-,61-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,81-/m0/s1",JMNJYGMAUMANNW-FIXZTSJVSA-N,Agonist,Full agonist,,yes,,,pKi,,8.1,,,,,,,,,,9686407, μ receptor,319,P35372,Human,dynorphin A-(1-8),1621,"Human, Mouse, Rat",108135,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C46H72N14O10/c1-5-27(4)38(44(69)70)60-41(66)33(14-10-20-53-46(50)51)57-40(65)32(13-9-19-52-45(48)49)58-42(67)34(21-26(2)3)59-43(68)35(23-28-11-7-6-8-12-28)56-37(63)25-54-36(62)24-55-39(64)31(47)22-29-15-17-30(61)18-16-29/h6-8,11-12,15-18,26-27,31-35,38,61H,5,9-10,13-14,19-25,47H2,1-4H3,(H,54,62)(H,55,64)(H,56,63)(H,57,65)(H,58,67)(H,59,68)(H,60,66)(H,69,70)(H4,48,49,52)(H4,50,51,53)/t27-,31-,32-,33-,34-,35-,38-/m0/s1",WRPLGMBDXVBPEG-VGXZEHLRSA-N,Agonist,Full agonist,,yes,,,pKi,,8.4,,,,,,,,,,9686407, μ receptor,319,P35372,Human,dynorphin B,1622,"Human, Mouse, Rat",25075991,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)[C@H](O)C)C(C)C)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(cc1)O)N)CC(C)C)CCCN=C(N)N)CCCN=C(N)N)CCC(=O)N)Cc1ccccc1,"InChI=1S/C74H115N21O17/c1-40(2)34-53(91-68(107)54(36-44-18-10-8-11-19-44)86-58(100)39-84-57(99)38-85-62(101)48(76)35-46-25-27-47(97)28-26-46)67(106)89-51(24-17-33-83-74(80)81)63(102)87-50(23-16-32-82-73(78)79)64(103)90-52(29-30-56(77)98)65(104)92-55(37-45-20-12-9-13-21-45)69(108)88-49(22-14-15-31-75)66(105)93-59(41(3)4)70(109)94-60(42(5)6)71(110)95-61(43(7)96)72(111)112/h8-13,18-21,25-28,40-43,48-55,59-61,96-97H,14-17,22-24,29-39,75-76H2,1-7H3,(H2,77,98)(H,84,99)(H,85,101)(H,86,100)(H,87,102)(H,88,108)(H,89,106)(H,90,103)(H,91,107)(H,92,104)(H,93,105)(H,94,109)(H,95,110)(H,111,112)(H4,78,79,82)(H4,80,81,83)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,59+,60+,61+/m1/s1",AGTSSZRZBSNTGQ-ITZCFHCWSA-N,Agonist,Full agonist,,yes,,,pKi,,8.5,,,,,,,,,,9686407, μ receptor,319,P35372,Human,endomorphin-1,1623,Human,5311080,Oc1ccc(cc1)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)Cc1c[nH]c2c1cccc2)N,"InChI=1S/C34H38N6O5/c35-26(17-22-12-14-24(41)15-13-22)34(45)40-16-6-11-30(40)33(44)39-29(19-23-20-37-27-10-5-4-9-25(23)27)32(43)38-28(31(36)42)18-21-7-2-1-3-8-21/h1-5,7-10,12-15,20,26,28-30,37,41H,6,11,16-19,35H2,(H2,36,42)(H,38,43)(H,39,44)/t26-,28-,29-,30-/m0/s1",ZEXLJFNSKAHNFH-SYKYGTKKSA-N,Agonist,Full agonist,,yes,,,pKi,,8.3,,Ki,,5.01,,=,,,,9849897|9087409, μ receptor,319,P35372,Human,etonitazene,1624,,13493,CCOc1ccc(cc1)Cc1nc2c(n1CCN(CC)CC)ccc(c2)[N+](=O)[O-],"InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3",PXDBZSCGSQSKST-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pEC50,,10.52,,EC50,,0.03,,=,Potency determined as inhibition of cAMP accumulation in a Gi-cAMP assay,,,37658878, μ receptor,319,P35372,Human,etonitazene,1624,,13493,CCOc1ccc(cc1)Cc1nc2c(n1CCN(CC)CC)ccc(c2)[N+](=O)[O-],"InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3",PXDBZSCGSQSKST-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,9.7,,,,,,,,,,9686407, μ receptor,319,P33535,Rat,etonitazene,1624,,13493,CCOc1ccc(cc1)Cc1nc2c(n1CCN(CC)CC)ccc(c2)[N+](=O)[O-],"InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3",PXDBZSCGSQSKST-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,8.18,,Ki,,6.6,,=,Binding affinity determined in radioligand displacement assay using rat brain and [3H]DAMGO as tracer,,,37658878, μ receptor,319,P35372,Human,etorphine,1625,,518962,CCCC(C1CC23C=CC1(OC)C1C43CCN(C2Cc2c4c(O1)c(O)cc2)C)(O)C,"InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3",CAHCBJPUTCKATP-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,9.5,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,fentanyl,1626,,3345,CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",PJMPHNIQZUBGLI-UHFFFAOYSA-N,Agonist,Full agonist,,,yes,,pKi,,9.2,,,,,,=,,,,9686407, μ receptor,319,P33535,Rat,fentanyl,1626,,3345,CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",PJMPHNIQZUBGLI-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,9.4,,,,,,,,,,8114680, μ receptor,319,P35372,Human,morphine,1627,,5288826,O[C@H]1C=C[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O,"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",BQJCRHHNABKAKU-KBQPJGBKSA-N,Agonist,Full agonist,,,yes,,pKi,,9.0,,,,,,=,,,,9686407|2549383, μ receptor,319,P33535,Rat,morphine,1627,,5288826,O[C@H]1C=C[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O,"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",BQJCRHHNABKAKU-KBQPJGBKSA-N,Agonist,Partial agonist,,,,,pKi,,7.9,,,,,,,,,,8114680, μ receptor,319,P35372,Human,nalmefene,1628,,5284594,C=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,"InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1",WJBLNOPPDWQMCH-MBPVOVBZSA-N,Antagonist,Antagonist,,,yes,,pKi,,9.5,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,nalorphine,1629,,5284595,C=CCN1CC[C@@]23[C@@H]4[C@H]1Cc1c3c(O[C@H]2[C@H](C=C4)O)c(cc1)O,"InChI=1S/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1",UIQMVEYFGZJHCZ-SSTWWWIQSA-N,Antagonist,Antagonist,,,yes,,pKi,,8.9,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,normorphine,1630,,5462508,O[C@H]1C=C[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2NCC3)ccc1O,"InChI=1S/C16H17NO3/c18-11-3-1-8-7-10-9-2-4-12(19)15-16(9,5-6-17-10)13(8)14(11)20-15/h1-4,9-10,12,15,17-19H,5-7H2/t9-,10+,12-,15-,16-/m0/s1",ONBWJWYUHXVEJS-ZTYRTETDSA-N,Agonist,Full agonist,,,,,pKi,,8.8,,,,,,,,,,9686407, μ receptor,319,P35372,Human,β-FNA,1631,,5311018,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,"InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29)/b7-6+/t16-,18-,23+,24+,25-/m1/s1",PQKHESYTSKMWFP-WZJCLRDWSA-N,Antagonist,Antagonist,,,,,pKi,,9.5,,,,,,,,,,9686407, μ receptor,319,P42866,Mouse,β-FNA,1631,,5311018,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,"InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29)/b7-6+/t16-,18-,23+,24+,25-/m1/s1",PQKHESYTSKMWFP-WZJCLRDWSA-N,Antagonist,Antagonist,,,,,pKi,,9.5,,,,,,,,,,8114680, μ receptor,319,P35372,Human,quadazocine,1633,,115077,O=C(CCC1(C)[C@H]2Cc3c([C@]1(C)CCN2C)cc(cc3)O)CCC1CCCC1,"InChI=1S/C25H37NO2/c1-24-14-15-26(3)23(16-19-9-11-21(28)17-22(19)24)25(24,2)13-12-20(27)10-8-18-6-4-5-7-18/h9,11,17-18,23,28H,4-8,10,12-16H2,1-3H3/t23-,24+,25?/m1/s1",LOYWOYCPSWPKFH-CSIQULDISA-N,Antagonist,Antagonist,,,,,pKi,,10.0,,,,,,,,,,9686407, μ receptor,319,P35372,Human,BNTX,1634,,6438353,O=C1/C(=C\c2ccccc2)/C[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,"InChI=1S/C27H27NO4/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17/h1-5,8-9,12,17,21,25,29,31H,6-7,10-11,13-15H2/b19-12-/t21-,25+,26+,27-/m1/s1",WXOUFNFMPVMGFZ-XEGDMQTMSA-N,Antagonist,Antagonist,,,,,pKi,,8.8,,,,,,,,,,9686407, μ receptor,319,P35372,Human,CTAP,1635,,44309215,NC(=NCCC[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC([C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)C(=O)N[C@H](C(=O)N)[C@H](O)C)(C)C)NC(=O)[C@H](Cc1ccccc1)N)Cc1c[nH]c2c1cccc2)N,"InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33+,35+,36+,37+,38+,39+,40+,41-/m1/s1",OFMQLVRLOGHAJI-RWMSPKCPSA-N,Antagonist,Antagonist,,,,,pKi,,8.6,,,,,,=,,,,9686407|6313901, μ receptor,319,P35372,Human,naloxone,1638,,5284596,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",UZHSEJADLWPNLE-GRGSLBFTSA-N,Antagonist,Antagonist,,,,,pKi,,8.9,,,,,,=,,,,9686407, μ receptor,319,P42866,Mouse,naloxone,1638,,5284596,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",UZHSEJADLWPNLE-GRGSLBFTSA-N,Antagonist,Antagonist,,,,,pKi,,9.0,,,,,,,,,,8114680, μ receptor,319,P35372,Human,naltrexone,1639,,5360515,O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,"InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1",DQCKKXVULJGBQN-XFWGSAIBSA-N,Antagonist,Antagonist,,,yes,,pKi,9.7,,9.15,Ki,0.71,,0.199,=,,,,9686407|24973897, μ receptor,319,P35372,Human,naltriben,1640,,5486827,Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)Cc2c1oc1c2cccc1)CC1CC1,"InChI=1S/C26H25NO4/c28-18-8-7-15-11-20-26(29)12-17-16-3-1-2-4-19(16)30-22(17)24-25(26,21(15)23(18)31-24)9-10-27(20)13-14-5-6-14/h1-4,7-8,14,20,24,28-29H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1",ZHVWWEYETMPAMX-IFKAHUTRSA-N,Antagonist,Antagonist,,,,,pKi,,7.9,,,,,,,,,,9686407, μ receptor,319,P35372,Human,naltrindole,1641,,5497186,Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)Cc2c1[nH]c1c2cccc1)CC1CC1,"InChI=1S/C26H26N2O3/c29-19-8-7-15-11-20-26(30)12-17-16-3-1-2-4-18(16)27-22(17)24-25(26,21(15)23(19)31-24)9-10-28(20)13-14-5-6-14/h1-4,7-8,14,20,24,27,29-30H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1",WIYUZYBFCWCCQJ-IFKAHUTRSA-N,Antagonist,Antagonist,,,,,pKi,,8.2,,,,,,,,,,9686407, μ receptor,319,P35372,Human,nor-binaltorphimine,1642,,5480230,Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)Cc2c1[nH]c1c2C[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O)CC1CC1,"InChI=1S/C40H43N3O6/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2/t27-,28-,35+,36+,37+,38+,39-,40-/m1/s1",APSUXPSYBJVPPS-YAUKWVCOSA-N,Antagonist,Antagonist,,,,,pKi,,7.7,,,,,,,,,,9686407, μ receptor,319,P33535,Rat,β-endorphin,1643,Human,16132316,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)[C@@H](C)CC,"InChI=1S/C158H251N39O46S/c1-17-84(9)126(153(237)182-102(44-29-34-65-163)137(221)186-112(74-118(166)206)142(226)171-86(11)131(215)183-110(73-94-48-52-96(204)53-49-94)146(230)177-99(41-26-31-62-160)135(219)175-98(40-25-30-61-159)134(218)170-78-122(210)173-106(158(242)243)56-59-124(213)214)193-154(238)127(85(10)18-2)192-132(216)87(12)172-143(227)113(75-119(167)207)185-136(220)100(42-27-32-63-161)178-147(231)111(72-92-38-23-20-24-39-92)184-144(228)107(68-81(3)4)188-155(239)129(89(14)201)195-152(236)125(83(7)8)191-148(232)108(69-82(5)6)187-151(235)116-45-35-66-197(116)157(241)130(90(15)202)196-140(224)103(54-57-117(165)205)179-149(233)114(79-198)189-138(222)101(43-28-33-64-162)176-139(223)104(55-58-123(211)212)180-150(234)115(80-199)190-156(240)128(88(13)200)194-141(225)105(60-67-244-16)181-145(229)109(71-91-36-21-19-22-37-91)174-121(209)77-168-120(208)76-169-133(217)97(164)70-93-46-50-95(203)51-47-93/h19-24,36-39,46-53,81-90,97-116,125-130,198-204H,17-18,25-35,40-45,54-80,159-164H2,1-16H3,(H2,165,205)(H2,166,206)(H2,167,207)(H,168,208)(H,169,217)(H,170,218)(H,171,226)(H,172,227)(H,173,210)(H,174,209)(H,175,219)(H,176,223)(H,177,230)(H,178,231)(H,179,233)(H,180,234)(H,181,229)(H,182,237)(H,183,215)(H,184,228)(H,185,220)(H,186,221)(H,187,235)(H,188,239)(H,189,222)(H,190,240)(H,191,232)(H,192,216)(H,193,238)(H,194,225)(H,195,236)(H,196,224)(H,211,212)(H,213,214)(H,242,243)/t84-,85-,86-,87-,88+,89+,90+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,125-,126-,127-,128-,129-,130-/m0/s1",JMHFFDIMOUKDCZ-NTXHZHDSSA-N,Agonist,Full agonist,,,,,pKi,,9.0,,,,,,=,,,,8114680, μ receptor,319,P35372,Human,DAMGO,1647,,5462471,OCCNC(=O)[C@@H](N(C(=O)CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)C)Cc1ccccc1,"InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1",HPZJMUBDEAMBFI-WTNAPCKOSA-N,Agonist,Full agonist,,,,,pKi,,9.3,,,,,,=,,,,9686407|6263640, μ receptor,319,P33535,Rat,DAMGO,1647,,5462471,OCCNC(=O)[C@@H](N(C(=O)CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)C)Cc1ccccc1,"InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1",HPZJMUBDEAMBFI-WTNAPCKOSA-N,Agonist,Full agonist,,,,,pKi,,8.7,,,,,,,,,,8114680, μ receptor,319,P35372,Human,nalbuphine,1663,,5311304,O[C@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CCC2)ccc1O)O,"InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1",NETZHAKZCGBWSS-CEDHKZHLSA-N,Agonist,Partial agonist,,,yes,,pKi,,8.8,,Ki,,1.6,,=,,,,19282177, μ receptor,319,P35372,Human,naloxone benzoylhydrazone,1664,,9601084,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2/C(=N/NC(=O)c2ccccc2)/CC4)c(cc1)O)O,"InChI=1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)/b27-18+/t20-,23+,25+,26-/m1/s1",AKXCFAYOTIEFOH-XTNAHFASSA-N,Antagonist,Antagonist,,,,,pKi,,8.7,,,,,,,,,,9686407, μ receptor,319,P35372,Human,naloxone benzoylhydrazone,1664,,9601084,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2/C(=N/NC(=O)c2ccccc2)/CC4)c(cc1)O)O,"InChI=1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)/b27-18+/t20-,23+,25+,26-/m1/s1",AKXCFAYOTIEFOH-XTNAHFASSA-N,Antagonist,Antagonist,,,,,pKi,,8.2,,,,,,,,,,9686407, μ receptor,319,P35372,Human,buprenorphine,1670,,644073,CO[C@]12CC[C@]3(C[C@@H]1[C@@](C(C)(C)C)(O)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3N(CC1)CC1CC1)ccc2O,"InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",RMRJXGBAOAMLHD-IHFGGWKQSA-N,Agonist,Partial agonist,,,yes,,pKi,,8.8,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,PL017,1671,,115335,Oc1ccc(cc1)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N([C@H](C(=O)N1CCC[C@@H]1C(=O)N)Cc1ccccc1)C)N,"InChI=1S/C29H37N5O5/c1-32(25(18-19-7-3-2-4-8-19)29(39)33-15-5-9-23(33)26(31)36)28(38)24-10-6-16-34(24)27(37)22(30)17-20-11-13-21(35)14-12-20/h2-4,7-8,11-14,22-25,35H,5-6,9-10,15-18,30H2,1H3,(H2,31,36)/t22-,23+,24-,25-/m0/s1",JAKBYSTWCHUQOK-NDBXHCKUSA-N,Agonist,Full agonist,,,,,pKi,,8.2,,,,,,=,,,,9686407|6313901, μ receptor,319,P35372,Human,codeine,1673,,5284371,COc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@@H]4C=C[C@@H]1O)C,"InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1",OROGSEYTTFOCAN-DNJOTXNNSA-N,Agonist,Full agonist,,,yes,,pKi,,6.9,,,,,,=,,,,9686407, μ receptor,319,P35372,Human,CTOP,1674,,5311058,NCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CSSC([C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)C(=O)N[C@H](C(=O)N)[C@H](O)C)(C)C)NC(=O)[C@@H](Cc1ccccc1)N)Cc1ccc(cc1)O)Cc1c[nH]c2c1cccc2,"InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1",PZWWYAHWHHNCHO-FGHAYEPSSA-N,Antagonist,Antagonist,,,,,pKi,,9.7,,,,,,=,,,,8114680|2872570, μ receptor,319,P33535,Rat,[3H]naloxone,1676,,5284596,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",UZHSEJADLWPNLE-GRGSLBFTSA-N,Antagonist,Antagonist,,,,,pKd,9.0,,8.55,Kd,2.8,,1.0,=,CHO and BHK cell lines stably expressing the rat μ receptor,,,8913353, μ receptor,319,P42866,Mouse,naloxonazine,1677,,9576413,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2/C(=N\N=C/2\CC[C@@]3([C@@]56[C@H]2Oc2c6c(C[C@H]3N(CC5)CC=C)ccc2O)O)/CC4)c(cc1)O)O,"InChI=1S/C38H42N4O6/c1-3-15-41-17-13-35-29-21-5-7-25(43)31(29)47-33(35)23(9-11-37(35,45)27(41)19-21)39-40-24-10-12-38(46)28-20-22-6-8-26(44)32-30(22)36(38,34(24)48-32)14-18-42(28)16-4-2/h3-8,27-28,33-34,43-46H,1-2,9-20H2/b39-23-,40-24-/t27-,28-,33+,34+,35+,36+,37-,38-/m1/s1",AJPSBXJNFJCCBI-HNJBNLCWSA-N,Antagonist,Antagonist,,,,,pKi,,10.3,,,,,,,,,,8114680, μ receptor,319,P35372,Human,sufentanil,3534,,41693,COCC1(CCN(CC1)CCc1cccs1)N(c1ccccc1)C(=O)CC,"InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3",GGCSSNBKKAUURC-UHFFFAOYSA-N,Agonist,Full agonist,,,yes,,pKi,,9.9,,Ki,,0.138,,=,,,,21215785, μ receptor,319,P33535,Rat,sufentanil,3534,,41693,COCC1(CCN(CC1)CCc1cccs1)N(c1ccccc1)C(=O)CC,"InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3",GGCSSNBKKAUURC-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,9.1,,Ki,,0.77,,=,,,,2843777, μ receptor,319,P33535,Rat,endomorphin-2,3668,Human,5311081,Oc1ccc(cc1)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)Cc1ccccc1)N,"InChI=1S/C32H37N5O5/c33-25(18-23-13-15-24(38)16-14-23)32(42)37-17-7-12-28(37)31(41)36-27(20-22-10-5-2-6-11-22)30(40)35-26(29(34)39)19-21-8-3-1-4-9-21/h1-6,8-11,13-16,25-28,38H,7,12,17-20,33H2,(H2,34,39)(H,35,40)(H,36,41)/t25-,26-,27-,28-/m0/s1",XIJHWXXXIMEHKW-LJWNLINESA-N,Agonist,Full agonist,,yes,,,pKi,,8.5,,Ki,,3.24,,=,,,,9087409, μ receptor,319,P33535,Rat,[3H]DAMGO,3815,,,,,,Agonist,Full agonist,,,,,pKd,,9.2,,Kd,,0.57,,=,,,,8114680, μ receptor,319,P33535,Rat,[3H]PL017,3832,,,,,,Agonist,Agonist,,,,,,,,,,,,,=,,,,3030778, μ receptor,319,P35372,Human,methadone,5458,,4095,CCC(=O)C(c1ccccc1)(c1ccccc1)CC(N(C)C)C,"InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3",USSIQXCVUWKGNF-UHFFFAOYSA-N,Agonist,Agonist,,,yes,,pIC50,,8.39,,IC50,,4.1,,=,Binding affinity against μ-opioid receptor (human) using [3H]DAMGO radioligand.,,,11585443, μ receptor,319,P35372,Human,hydrocodone,7081,,5284569,COc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@@H]4CCC1=O)C,"InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1",LLPOLZWFYMWNKH-CMKMFDCUSA-N,Agonist,Agonist,,,yes,,pKi,,8.7,,Ki,,2.0,,=,,,,22439881, μ receptor,319,P35372,Human,hydromorphone,7082,,5284570,O=C1CC[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O,"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1",WVLOADHCBXTIJK-YNHQPCIGSA-N,Agonist,Agonist,,,yes,,pKi,,9.55,,Ki,,0.28,,=,,,,19282177, μ receptor,319,P35372,Human,levallorphan,7209,,5359371,C=CCN1CC[C@@]23[C@H]([C@H]1Cc1c3cc(cc1)O)CCCC2,"InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1",OZYUPQUCAUTOBP-QXAKKESOSA-N,Antagonist,Antagonist,,,yes,,pKi,9.32,,8.77,Ki,1.69,,0.48,=,Competition binding assay- the calculated Ki varies depending on the radioligand used.,,,21621410, μ receptor,319,P35372,Human,loperamide,7215,,3955,Clc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1,"InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3",RDOIQAHITMMDAJ-UHFFFAOYSA-N,Agonist,Agonist,,,yes,,pKi,,9.28,,Ki,,0.53,,=,,,,15454210, μ receptor,319,P35372,Human,pethidine,7221,,4058,CCOC(=O)C1(CCN(CC1)C)c1ccccc1,"InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3",XADCESSVHJOZHK-UHFFFAOYSA-N,Agonist,Agonist,,,yes,,pIC50,,6.5,,IC50,,315.0,,=,,,,11585443, μ receptor,319,P35372,Human,alvimopan,7471,,5488548,OC(=O)CNC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@]([C@H](C1)C)(C)c1cccc(c1)O,"InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1",UPNUIXSCZBYVBB-JVFUWBCBSA-N,Antagonist,Antagonist,peripheral,,yes,,pKi,,9.33,,Ki,,0.47,,=,,,,18313920, μ receptor,319,P35372,Human,tapentadol,7477,,9838022,CC[C@@H](c1cccc(c1)O)[C@H](CN(C)C)C,"InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1",KWTWDQCKEHXFFR-SMDDNHRTSA-N,Agonist,Agonist,,,yes,,pKi,,6.8,,Ki,,160.0,,=,,,,17656655, μ receptor,319,P35372,Human,methylnaltrexone,7563,,5361918,O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2[N+](CC3)(C)CC2CC2)ccc1O)O,"InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22?/m1/s1",JVLBPIPGETUEET-GAAHOAFPSA-O,Antagonist,Antagonist,,,yes,,pKi,,8.7,,Ki,,2.0,,=,Displacement of [3H]DAMGO from human μ opioid receptors expressed in CHO cells,,,19282177, μ receptor,319,P35372,Human,butorphanol,7591,,5361092,Oc1ccc2c(c1)[C@]13CCCC[C@]3([C@@H](C2)N(CC1)CC1CCC1)O,"InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1",IFKLAQQSCNILHL-QHAWAJNXSA-N,Agonist,Partial agonist,,,yes,,pKi,,9.92,,Ki,,0.12,,=,Displacement of [3H]DAMGO from human μ opioid receptor expressed in CHO cells.,,,18674902, μ receptor,319,P35372,Human,levorphanol,7595,,5359272,Oc1ccc2c(c1)[C@]13CCCC[C@H]3[C@@H](C2)N(CC1)C,"InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1",JAQUASYNZVUNQP-USXIJHARSA-N,Agonist,Agonist,,,yes,,pIC50,,9.89,,IC50,,0.13,,=,,,,12502358, μ receptor,319,P35372,Human,eluxadoline,7691,,11250029,COc1ccc(cc1C(=O)O)CN([C@H](c1ncc([nH]1)c1ccccc1)C)C(=O)[C@H](Cc1c(C)cc(cc1C)C(=O)N)N,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1",QFNHIDANIVGXPE-FNZWTVRRSA-N,Agonist,Agonist,,,,,pKi,,8.77,,Ki,,1.7,,=,,,,22695132, μ receptor,319,P33535,Rat,eluxadoline,7691,,11250029,COc1ccc(cc1C(=O)O)CN([C@H](c1ncc([nH]1)c1ccccc1)C)C(=O)[C@H](Cc1c(C)cc(cc1C)C(=O)N)N,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1",QFNHIDANIVGXPE-FNZWTVRRSA-N,Agonist,Agonist,,,,,pKi,,9.05,,Ki,,0.9,,=,,,,22695132, μ receptor,319,P35372,Human,tramadol,8286,,5523,COc1cccc(c1)C1(O)CCCCC1CN(C)C,"InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3",TVYLLZQTGLZFBW-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,5.8,,Ki,,1600.0,,=,Displacement of the mu aginist peptide DAMGO from the mu receptor expressed in CHO cells.,,,19282177, μ receptor,319,P35372,Human,cebranopadol,8866,,11848225,Fc1ccc2c(c1)c1CCOC3(c1[nH]2)CCC(CC3)(N(C)C)c1ccccc1,"InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3",CSMVOZKEWSOFER-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,9.15,,Ki,,0.7,,=,Radioligand binding assay,,,24713140, μ receptor,319,P33535,Rat,cebranopadol,8866,,11848225,Fc1ccc2c(c1)c1CCOC3(c1[nH]2)CCC(CC3)(N(C)C)c1ccccc1,"InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3",CSMVOZKEWSOFER-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,8.62,,Ki,,2.4,,=,Radioligand binding assay,,,24713140, μ receptor,319,P35372,Human,SR16835,8867,,49843739,O=C1Cc2c(N1C1CCN(CC1)C1CCC3c4c1cccc4CCC3)cccc2,"InChI=1S/C26H30N2O/c29-25-17-20-5-1-2-10-23(20)28(25)21-13-15-27(16-14-21)24-12-11-19-7-3-6-18-8-4-9-22(24)26(18)19/h1-2,4-5,8-10,19,21,24H,3,6-7,11-17H2",SZKWDIATUVLAAW-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,7.1,,Ki,,79.9,,=,Radioligand binding assay,,,19773529, μ receptor,319,P35372,Human,SCH221510,8868,,9887077,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(C2)(O)c1ccccc1,"InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3",LOSJNRBXNQTUNT-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,7.19,,Ki,,65.0,,=,Radioligand binding assay,,,18492950, μ receptor,319,P35372,Human,AT-076,8870,,91938095,Oc1ccc2c(c1)CN[C@H](C2)C(=O)N[C@@H](C(C)C)CN1CCC(CC1)c1cccc(c1)O,"InChI=1S/C26H35N3O3/c1-17(2)25(16-29-10-8-18(9-11-29)19-4-3-5-22(30)12-19)28-26(32)24-14-20-6-7-23(31)13-21(20)15-27-24/h3-7,12-13,17-18,24-25,27,30-31H,8-11,14-16H2,1-2H3,(H,28,32)/t24-,25-/m1/s1",LGYDWJJZDCXEOV-JWQCQUIFSA-N,Antagonist,Antagonist,,,,,pKi,,8.78,,Ki,,1.67,,=,Radioligand binding assay,,,9686407|25635572, μ receptor,319,P35372,Human,BW373U86,9002,,119029,C=CCN1C[C@H](C)N(C[C@H]1C)[C@@H](c1cccc(c1)O)c1ccc(cc1)C(=O)N(CC)CC,"InChI=1S/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3/t20-,21+,26-/m1/s1",LBLDMHBSVIVJPM-YZIHRLCOSA-N,Agonist,Agonist,,,,,pKi,,6.59,,Ki,,260.0,,=,,,,18788723, μ receptor,319,P33535,Rat,BW373U86,9002,,119029,C=CCN1C[C@H](C)N(C[C@H]1C)[C@@H](c1cccc(c1)O)c1ccc(cc1)C(=O)N(CC)CC,"InChI=1S/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3/t20-,21+,26-/m1/s1",LBLDMHBSVIVJPM-YZIHRLCOSA-N,Agonist,Agonist,,,,,pKi,,7.82,,Ki,,15.0,,=,,,,8246159, μ receptor,319,P35372,Human,ADL5747,9003,,11200189,CCN(C(=O)c1ccc(c(c1)O)C1=CC2(CCNCC2)Oc2c1cccc2)CC,"InChI=1S/C24H28N2O3/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3",ALGHKWSXJUQNJJ-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,7.74,,Ki,,18.0,,=,,,,19694468, μ receptor,319,P35372,Human,ADL5859,9004,,11417954,CCN(C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2c1c(O)ccc2)CC,"InChI=1S/C24H28N2O3/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21/h5-11,16,25,27H,3-4,12-15H2,1-2H3",OPIKUXLJQFYMSC-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,7.49,,Ki,,32.0,,=,,,,18788723, μ receptor,319,P35372,Human,AR-M1000390,9005,,9841259,CCN(C(=O)c1ccc(cc1)C(=C1CCNCC1)c1ccccc1)CC,"InChI=1S/C23H28N2O/c1-3-25(4-2)23(26)21-12-10-19(11-13-21)22(18-8-6-5-7-9-18)20-14-16-24-17-15-20/h5-13,24H,3-4,14-17H2,1-2H3",SMUGAZNLKPFBSB-UHFFFAOYSA-N,Agonist,Agonist,,,,,pIC50,,5.42,,IC50,,3800.0,,=,,,,, μ receptor,319,P35372,Human,UFP-512,9006,,10918703,Oc1cc(C)c(c(c1)C)C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)N[C@H](c1[nH]c2c(n1)cccc2)CC(=O)O)N,"InChI=1S/C31H33N5O5/c1-17-11-21(37)12-18(2)22(17)14-23(32)31(41)36-16-20-8-4-3-7-19(20)13-27(36)30(40)35-26(15-28(38)39)29-33-24-9-5-6-10-25(24)34-29/h3-12,23,26-27,37H,13-16,32H2,1-2H3,(H,33,34)(H,35,40)(H,38,39)/t23-,26-,27-/m0/s1",USVQTDLSVBRMCR-YGPDHOBYSA-N,Agonist,Agonist,,,,,pKi,,8.0,,,,,,=,Measuring displacement of [3H]-diprenorphine in vitro,,,18069089, μ receptor,319,P35372,Human,naldemedine,9150,,54732242,O=C(C1=C(O)[C@H]2[C@]34[C@](C1)(O)[C@@H](Cc1c4c(O2)c(O)cc1)N(CC3)CC1CC1)NC(c1onc(n1)c1ccccc1)(C)C,"InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1",AXQACEQYCPKDMV-RZAWKFBISA-N,Antagonist,Antagonist,,,yes,,pKi,,8.95,,Ki,,1.13,,=,,,,30446313, μ receptor,319,P35372,Human,BMS-986121,9156,,121231403,Clc1cccc(c1Nc1scc(n1)c1ccc(cc1)N(O)[O])Cl,"InChI=1S/C15H10Cl2N3O2S/c16-11-2-1-3-12(17)14(11)19-15-18-13(8-23-15)9-4-6-10(7-5-9)20(21)22/h1-8,21H,(H,18,19)",XUVKOFBHMYDXMJ-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,pEC50,,6.0,,EC50,,1000.0,,=,,,,23754417, μ receptor,319,P35372,Human,BMS-986121,9156,,121231403,Clc1cccc(c1Nc1scc(n1)c1ccc(cc1)N(O)[O])Cl,"InChI=1S/C15H10Cl2N3O2S/c16-11-2-1-3-12(17)14(11)19-15-18-13(8-23-15)9-4-6-10(7-5-9)20(21)22/h1-8,21H,(H,18,19)",XUVKOFBHMYDXMJ-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,pKB,,5.7,,KB,,2000.0,,=,,,,23754417, μ receptor,319,P35372,Human,BMS-986122,9157,,4644453,COc1ccc(cc1Br)C1SCCN1S(=O)(=O)c1ccc(cc1)Cl,"InChI=1S/C16H15BrClNO3S2/c1-22-15-7-2-11(10-14(15)17)16-19(8-9-23-16)24(20,21)13-5-3-12(18)4-6-13/h2-7,10,16H,8-9H2,1H3",PNGJPVDGZNPZHY-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,pEC50,,5.52,,EC50,,3000.0,,=,,,,23754417, μ receptor,319,P35372,Human,BMS-986122,9157,,4644453,COc1ccc(cc1Br)C1SCCN1S(=O)(=O)c1ccc(cc1)Cl,"InChI=1S/C16H15BrClNO3S2/c1-22-15-7-2-11(10-14(15)17)16-19(8-9-23-16)24(20,21)13-5-3-12(18)4-6-13/h2-7,10,16H,8-9H2,1H3",PNGJPVDGZNPZHY-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,pKB,,5.3,,KB,,5000.0,,=,,,,23754417, μ receptor,319,P35372,Human,BMS-986123,9159,,121231404,COc1ccc(cc1N(O)[O])C1SCCN1S(=O)(=O)c1ccc(cc1)C,"InChI=1S/C17H19N2O5S2/c1-12-3-6-14(7-4-12)26(22,23)18-9-10-25-17(18)13-5-8-16(24-2)15(11-13)19(20)21/h3-8,11,17,20H,9-10H2,1-2H3",AXAIHSGKCYUSAN-UHFFFAOYSA-N,Allosteric modulator,Neutral,,,,,pKB,,6.0,,KB,,1000.0,,=,,,,23754417, μ receptor,319,P35372,Human,BMS-986124,9160,,121231405,COc1cc(Br)ccc1C1SCCN1S(=O)(=O)c1ccc(cc1)Cl,"InChI=1S/C16H15BrClNO3S2/c1-22-15-10-11(17)2-7-14(15)16-19(8-9-23-16)24(20,21)13-5-3-12(18)4-6-13/h2-7,10,16H,8-9H2,1H3",PMPBBWPDHSHENJ-UHFFFAOYSA-N,Allosteric modulator,Neutral,,,,,pKB,,5.7,,KB,,2000.0,,=,,,,23754417, μ receptor,319,P35372,Human,HS665,9189,,71452041,Oc1cccc(c1)CCN(CC1CCC1)CCc1ccccc1,"InChI=1S/C21H27NO/c23-21-11-5-8-19(16-21)13-15-22(17-20-9-4-10-20)14-12-18-6-2-1-3-7-18/h1-3,5-8,11,16,20,23H,4,9-10,12-15,17H2",YNVKFHIWFDRVNY-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,6.27,,Ki,,542.0,,=,,,,23134120, μ receptor,319,P35372,Human,compound 3 [PMID: 23134120],9190,,71452040,Oc1cccc(c1)CCN(CC1CC1)CCc1ccccc1,"InChI=1S/C20H25NO/c22-20-8-4-7-18(15-20)12-14-21(16-19-9-10-19)13-11-17-5-2-1-3-6-17/h1-8,15,19,22H,9-14,16H2",QURAQIGQNZYJHP-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,6.08,,Ki,,826.0,,=,,,,23134120, μ receptor,319,P35372,Human,zyklophin,9193,,45483651,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CNC(=O)C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccc(cc2)O)NCc2ccccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(CC)C)CCCN=C(N)N)CCCN=C(N)N,"InChI=1S/C65H96N20O13/c1-3-38(2)54-62(97)83-49(60(95)81-45(21-13-29-73-65(70)71)63(98)85-30-14-22-50(85)61(96)79-43(55(67)90)19-10-11-27-66)35-75-51(87)33-48(59(94)80-44(57(92)84-54)20-12-28-72-64(68)69)82-58(93)47(32-39-15-6-4-7-16-39)78-53(89)37-76-52(88)36-77-56(91)46(31-40-23-25-42(86)26-24-40)74-34-41-17-8-5-9-18-41/h4-9,15-18,23-26,38,43-50,54,74,86H,3,10-14,19-22,27-37,66H2,1-2H3,(H2,67,90)(H,75,87)(H,76,88)(H,77,91)(H,78,89)(H,79,96)(H,80,94)(H,81,95)(H,82,93)(H,83,97)(H,84,92)(H4,68,69,72)(H4,70,71,73)/t38?,43-,44-,45-,46-,47-,48-,49-,50-,54-/m0/s1",UWLIKQFWZOPOAX-HRFULILYSA-N,Antagonist,Antagonist,,,,,pKi,,5.23,,Ki,,5880.0,,=,,,,15999987, μ receptor,319,P35372,Human,LY2456302,9194,,44129648,Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(cc1)Oc1ccc(cc1F)C(=O)N,"InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1",ZHPMYDSXGRRERG-DEOSSOPVSA-N,Antagonist,Antagonist,,,,,pKi,,7.62,,Ki,,24.0,,=,,,,24071566, μ receptor,319,P33535,Rat,U-47700,9282,,13544016,CN([C@@H]1CCCC[C@H]1N(C(=O)c1ccc(c(c1)Cl)Cl)C)C,"InChI=1S/C16H22Cl2N2O/c1-19(2)14-6-4-5-7-15(14)20(3)16(21)11-8-9-12(17)13(18)10-11/h8-10,14-15H,4-7H2,1-3H3/t14-,15-/m1/s1",JGPNMZWFVRQNGU-HUUCEWRRSA-N,Agonist,Agonist,,,,,,,,,,,,,=,,,,2999404, μ receptor,319,P35372,Human,PZM21,9286,,121596705,C[C@@H](Cc1cscc1)NC(=O)NC[C@@H](N(C)C)Cc1ccc(cc1)O,"InChI=1S/C19H27N3O2S/c1-14(10-16-8-9-25-13-16)21-19(24)20-12-17(22(2)3)11-15-4-6-18(23)7-5-15/h4-9,13-14,17,23H,10-12H2,1-3H3,(H2,20,21,24)/t14-,17-/m0/s1",MEDBIJOVZJEMBI-YOEHRIQHSA-N,Agonist,Biased agonist,,,yes,,pEC50,,8.34,,EC50,,4.6,,=,In a Gi/o activation assay.,,,27533032, μ receptor,319,P35372,Human,PZM21,9286,,121596705,C[C@@H](Cc1cscc1)NC(=O)NC[C@@H](N(C)C)Cc1ccc(cc1)O,"InChI=1S/C19H27N3O2S/c1-14(10-16-8-9-25-13-16)21-19(24)20-12-17(22(2)3)11-15-4-6-18(23)7-5-15/h4-9,13-14,17,23H,10-12H2,1-3H3,(H2,20,21,24)/t14-,17-/m0/s1",MEDBIJOVZJEMBI-YOEHRIQHSA-N,Agonist,Biased agonist,,,yes,,pKi,,8.96,,Ki,,1.1,,=,,,,27533032, μ receptor,319,P35372,Human,GSK1521498,9287,,24737629,Fc1cc(cc(c1CNC1Cc2c(C1)cccc2)F)c1cccc(c1)c1ncn[nH]1,"InChI=1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)",WIEDUMBCZQRGSY-UHFFFAOYSA-N,Antagonist,Antagonist,,,yes,,pKi,,9.38,,Ki,,0.417,,=,,,,24973897, μ receptor,319,P35372,Human,BU08028,9294,,50922685,CO[C@]12CC[C@]3(C[C@@H]1[C@@](C(CC)(C)C)(O)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3N(CC1)CC1CC1)ccc2O,"InChI=1S/C30H43NO4/c1-6-26(2,3)27(4,33)21-16-28-11-12-30(21,34-5)25-29(28)13-14-31(17-18-7-8-18)22(28)15-19-9-10-20(32)24(35-25)23(19)29/h9-10,18,21-22,25,32-33H,6-8,11-17H2,1-5H3/t21-,22-,25-,27+,28-,29+,30-/m1/s1",HBENZIXOGRCSQN-VQWWACLZSA-N,Agonist,Partial agonist,,,,,pKi,,8.67,,Ki,,2.14,,=,,,,21177476, μ receptor,319,,Guinea pig,BU72,9363,,155804574,CO[C@@]12C=C[C@@]34[C@@]5([C@@H]1N[C@@H]([C@]2(C)C3)c1ccccc1)CCN([C@@H]4Cc1c5cc(O)cc1)C,"InChI=1S/C28H32N2O2/c1-25-17-26-11-12-28(25,32-3)24(29-23(25)18-7-5-4-6-8-18)27(26)13-14-30(2)22(26)15-19-9-10-20(31)16-21(19)27/h4-12,16,22-24,29,31H,13-15,17H2,1-3H3/t22-,23-,24+,25+,26-,27+,28+/m1/s1",RGJHUVJQGAAZLK-GKTFKBBASA-N,Agonist,Agonist,,,,,pIC50,,9.82,,IC50,,0.15,,=,Measuring displacement of [3H]DAMGO from brain membranes isolated from Hartley guinea pigs.,,,, μ receptor,319,P33535,Rat,BMS-986187,9748,,17379334,O=C1CC(C)(C)CC2=C1C(c1ccc(cc1)OCc1ccccc1C)C1=C(O2)CC(CC1=O)(C)C,"InChI=1S/C31H34O4/c1-19-8-6-7-9-21(19)18-34-22-12-10-20(11-13-22)27-28-23(32)14-30(2,3)16-25(28)35-26-17-31(4,5)15-24(33)29(26)27/h6-13,27H,14-18H2,1-5H3",UEKIYVKPQNKSDI-UHFFFAOYSA-N,Allosteric modulator,Positive,"In the presence of 10 μM BMS-986187, the affinity of the μ-OR agonist DAMGO was enhanced 11-fold from 724 nM to 63 nM.",,,,pKi,,7.2,,Ki,,63.0,,=,,,,29233847, μ receptor,319,P35372,Human,UFP-505,9838,,10864183,O=C(NCc1ccccc1)CNC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@H](Cc1c(C)cc(cc1C)O)N,"InChI=1S/C30H34N4O4/c1-19-12-24(35)13-20(2)25(19)15-26(31)30(38)34-18-23-11-7-6-10-22(23)14-27(34)29(37)33-17-28(36)32-16-21-8-4-3-5-9-21/h3-13,26-27,35H,14-18,31H2,1-2H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1",SYOVEDOWOXNOJG-SVBPBHIXSA-N,Agonist,Agonist,,,,,pKi,,7.79,,,,,,=,,,,22194444|29524334, μ receptor,319,,Guinea pig,carfentanil,10040,,62156,CCC(=O)N(C1(CCN(CC1)CCc1ccccc1)C(=O)OC)c1ccccc1,"InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3",YDSDEBIZUNNPOB-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,10.62,,Ki,,0.024,,=,Binding affinity in guinea pig whole brain- displacement of [3H]DAGO binding.,,,1310142, μ receptor,319,P35372,Human,NFP,10185,,137321165,Oc1ccc2c3c1O[C@@H]1C43CCN([C@H](C2)[C@]4(O)CC[C@H]1NC(=O)c1ccncc1F)CC1CC1,"InChI=1S/C26H28FN3O4/c27-17-12-28-9-6-16(17)24(32)29-18-5-7-26(33)20-11-15-3-4-19(31)22-21(15)25(26,23(18)34-22)8-10-30(20)13-14-1-2-14/h3-4,6,9,12,14,18,20,23,31,33H,1-2,5,7-8,10-11,13H2,(H,29,32)/t18-,20-,23+,25?,26-/m1/s1",JRUPWWCGTBJDNY-LNMFUWNLSA-N,Antagonist,Antagonist,,,,,pKi,,9.44,,Ki,,0.36,,=,In a competitive radioligand membrane binding assay measuring displacement of [3H]naloxone by NFP from μ receptor expressed in CHO cells.,,,30608693, μ receptor,319,P35372,Human,NMRA-140,10452,,137434175,CCc1cc(F)c2c(c1)c(C)c(c(n2)N1CCC(CC1)NC1CCOCC1)c1onc(n1)C,"InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3",CQOJHAJWCDJEAT-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.96,,IC50,,110.0,,=,,,,30707578, μ receptor,319,P35372,Human,compound 16 [PMID: 31498617],10482,,139030531,COc1ccccc1S(=O)(=O)Nc1ccc(cc1Oc1ccc2c(c1)ccnc2N)C,"InChI=1S/C23H21N3O4S/c1-15-7-10-19(26-31(27,28)22-6-4-3-5-20(22)29-2)21(13-15)30-17-8-9-18-16(14-17)11-12-25-23(18)24/h3-14,26H,1-2H3,(H2,24,25)",BWEJNHRMGZUMNU-UHFFFAOYSA-N,None,Binding,,,,,pKi,,5.43,,Ki,,3730.0,,=,Receptor binding in a radioligand displacement assay using [3H]DAMGO as tracer.,,,31498617, μ receptor,319,P35372,Human,bilorphin,10518,,139593559,Oc1cc(C)c(c(c1)C)C[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)Cc1ccccc1)C(C)C)C(C)C)N,"InChI=1S/C30H43N5O5/c1-16(2)25(29(39)33-24(27(32)37)14-20-10-8-7-9-11-20)35-30(40)26(17(3)4)34-28(38)23(31)15-22-18(5)12-21(36)13-19(22)6/h7-13,16-17,23-26,36H,14-15,31H2,1-6H3,(H2,32,37)(H,33,39)(H,34,38)(H,35,40)/t23-,24-,25-,26+/m1/s1",IYNDNOATOVLHNV-POTDNYQPSA-N,Agonist,Agonist,,,yes,,pKi,,8.96,,Ki,,1.1,,=,,,,31611414, μ receptor,319,P35372,Human,samidorphan,10651,,11667832,O=C1CC[C@@]2([C@@]3(C1)CCN([C@@H]2Cc1c3c(O)c(cc1)C(=O)N)CC1CC1)O,"InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1",RYIDHLJADOKWFM-MAODMQOUSA-N,Antagonist,Antagonist,,,,,pKi,,10.28,,Ki,,0.052,,=,,,,15808478, μ receptor,319,P35372,Human,oxycodegol,10652,,73673720,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1OC)O,"InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1",RQHILGKAOIGUHU-XPLSERNMSA-N,Agonist,Agonist,,,,,pKi,,6.63,,Ki,,237.0,,=,Competitive membrane binding assay measuring displacement [3H]naloxone from human μ receptors expressed by CHO cells.,,,28778859, μ receptor,319,P35372,Human,MT-45,10724,,431865,C1CCC(CC1)N1CCN(CC1)C(c1ccccc1)Cc1ccccc1,"InChI=1S/C24H32N2/c1-4-10-21(11-5-1)20-24(22-12-6-2-7-13-22)26-18-16-25(17-19-26)23-14-8-3-9-15-23/h1-2,4-7,10-13,23-24H,3,8-9,14-20H2",IGBRRSIHEGCUEN-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,4.64,,EC50,,23000.0,,=,β-arrestin2 recruitment assay,,,32246840, μ receptor,319,P35372,Human,2F-MT-45,10725,,132990975,Fc1ccccc1C(N1CCN(CC1)C1CCCCC1)Cc1ccccc1,"InChI=1S/C24H31FN2/c25-23-14-8-7-13-22(23)24(19-20-9-3-1-4-10-20)27-17-15-26(16-18-27)21-11-5-2-6-12-21/h1,3-4,7-10,13-14,21,24H,2,5-6,11-12,15-19H2",BZESPHAKQKJBSM-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,6.7,,EC50,,200.0,,=,β-arrestin2 recruitment assay,,,32246840, μ receptor,319,P35372,Human,3F-MT-45,10726,,132990929,Fc1cccc(c1)C(N1CCN(CC1)C1CCCCC1)Cc1ccccc1,"InChI=1S/C24H31FN2/c25-22-11-7-10-21(19-22)24(18-20-8-3-1-4-9-20)27-16-14-26(15-17-27)23-12-5-2-6-13-23/h1,3-4,7-11,19,23-24H,2,5-6,12-18H2",CGVHPULMBGGZPI-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,6.21,,EC50,,610.0,,=,β-arrestin2 recruitment assay,,,32246840, μ receptor,319,P35372,Human,4F-MT-45,10727,,132990963,Fc1ccc(cc1)C(N1CCN(CC1)C1CCCCC1)Cc1ccccc1,"InChI=1S/C24H31FN2/c25-22-13-11-21(12-14-22)24(19-20-7-3-1-4-8-20)27-17-15-26(16-18-27)23-9-5-2-6-10-23/h1,3-4,7-8,11-14,23-24H,2,5-6,9-10,15-19H2",AGKZEOCNYCHVLW-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,6.77,,EC50,,170.0,,=,β-arrestin2 recruitment assay,,,32246840, μ receptor,319,P35372,Human,ICI-199441,11691,,3082718,Clc1cc(ccc1Cl)CC(=O)N([C@H](CN1CCCC1)c1ccccc1)C,"InChI=1S/C21H24Cl2N2O/c1-24(21(26)14-16-9-10-18(22)19(23)13-16)20(15-25-11-5-6-12-25)17-7-3-2-4-8-17/h2-4,7-10,13,20H,5-6,11-12,14-15H2,1H3/t20-/m1/s1",AEJOEPSMZCEYJN-HXUWFJFHSA-N,Agonist,Agonist,,,,,pKi,,7.28,,Ki,,53.0,,=,Displacement of [3H]diprenorphine from human μ opioid receptor expressed in CHO-K1 cells,,,18487043, μ receptor,319,P35372,Human,SRI22141,11694,,71460944,CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@]2(Cc1c4ncc(c1)c1ccc(Cl)cc1)OCCCc1ccccc1)c35,"InChI=1S/C35H33ClN2O3/c1-38-16-15-34-30-24-11-14-28(39)32(30)41-33(34)31-25(18-26(21-37-31)23-9-12-27(36)13-10-23)20-35(34,29(38)19-24)40-17-5-8-22-6-3-2-4-7-22/h2-4,6-7,9-14,18,21,29,33,39H,5,8,15-17,19-20H2,1H3/t29-,33+,34+,35-/m1/s1",AQMQWKFSMIRRJA-OGICNVKRSA-N,Agonist,Agonist,,,,,pEC50,,9.7,,EC50,,0.2,,=,Potency in a 35S-GTPγS assay,,,31201990, μ receptor,319,P35372,Human,SRI22141,11694,,71460944,CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@]2(Cc1c4ncc(c1)c1ccc(Cl)cc1)OCCCc1ccccc1)c35,"InChI=1S/C35H33ClN2O3/c1-38-16-15-34-30-24-11-14-28(39)32(30)41-33(34)31-25(18-26(21-37-31)23-9-12-27(36)13-10-23)20-35(34,29(38)19-24)40-17-5-8-22-6-3-2-4-7-22/h2-4,6-7,9-14,18,21,29,33,39H,5,8,15-17,19-20H2,1H3/t29-,33+,34+,35-/m1/s1",AQMQWKFSMIRRJA-OGICNVKRSA-N,Agonist,Agonist,,,,,pKi,,7.71,,Ki,,19.7,,=,Binding affinity,,,31201990, μ receptor,319,P35372,Human,[3H]CTOP,12512,,,,,,Antagonist,Antagonist,,,,,,,,,,,,,=,,,,1968847, μ receptor,319,P42866,Mouse,DC 128.1,12726,,168433297,C(CC1=CC=CC=C1)N2[C@@H]3CCC[C@](CC2)([C@@H]3/C=C\C)C=4C=C(C=CC4)O,"InChI=1S/C25H31NO/c1-2-8-23-24-13-7-15-25(23,21-11-6-12-22(27)19-21)16-18-26(24)17-14-20-9-4-3-5-10-20/h2-6,8-12,19,23-24,27H,7,13-18H2,1H3/b8-2-/t23-,24-,25-/m1/s1",XGHUWVMRNBCUKH-FMNMTASSSA-N,Agonist,Agonist,,,,,pKi,,9.25,,Ki,,0.56,,=,"Binding affinity determined in a radioligand membrane binding assay, displacing [3H]naloxone",,,36234992, μ receptor,319,P42866,Mouse,DC-1-76.2,12727,,168433298,C(CC1=CC=CC=C1)N2[C@@H]3CCC[C@](CC2)([C@H]3C=C)C=4C=C(C=CC4)O,"InChI=1S/C24H29NO/c1-2-22-23-12-7-14-24(22,20-10-6-11-21(26)18-20)15-17-25(23)16-13-19-8-4-3-5-9-19/h2-6,8-11,18,22-23,26H,1,7,12-17H2/t22-,23+,24+/m0/s1",VYLFPTUCOJRQKZ-RBZQAINGSA-N,Agonist,Agonist,,,,,pKi,,9.3,,Ki,,0.5,,=,"Binding affinity determined in a radioligand membrane binding assay, displacing [3H]naloxone",,,36234992, μ receptor,319,P42866,Mouse,DC-1-90.2,12728,,168433299,C(CC1=CC=CC=C1)N2[C@@H]3CCC[C@](CC2)([C@H]3/C=C\C)C=4C=C(C=CC4)O,"InChI=1S/C25H31NO/c1-2-8-23-24-13-7-15-25(23,21-11-6-12-22(27)19-21)16-18-26(24)17-14-20-9-4-3-5-10-20/h2-6,8-12,19,23-24,27H,7,13-18H2,1H3/b8-2-/t23-,24+,25+/m0/s1",XGHUWVMRNBCUKH-OOXZDXTNSA-N,Agonist,Agonist,,,,,pKi,,8.74,,Ki,,1.83,,=,"Binding affinity determined in a radioligand membrane binding assay, displacing [3H]naloxone",,,36234992, μ receptor,319,P42866,Mouse,DC-1-76.1,12729,,168433300,C(CC1=CC=CC=C1)N2[C@@H]3CCC[C@](CC2)([C@@H]3C=C)C=4C=C(C=CC4)O,"InChI=1S/C24H29NO/c1-2-22-23-12-7-14-24(22,20-10-6-11-21(26)18-20)15-17-25(23)16-13-19-8-4-3-5-9-19/h2-6,8-11,18,22-23,26H,1,7,12-17H2/t22-,23-,24-/m1/s1",VYLFPTUCOJRQKZ-WXFUMESZSA-N,Agonist,Agonist,,,,,pKi,,8.72,,Ki,,1.91,,=,"Binding affinity determined in a radioligand membrane binding assay, displacing [3H]naloxone",,,36234992, μ receptor,319,P35372,Human,EWB-3-14,12730,,16757050,OC=1C=C(C=CC1)[C@]23CCN([C@H](CCC2)[C@@H]3C)CCC4=CC=CC=C4,"InChI=1S/C23H29NO/c1-18-22-11-6-13-23(18,20-9-5-10-21(25)17-20)14-16-24(22)15-12-19-7-3-2-4-8-19/h2-5,7-10,17-18,22,25H,6,11-16H2,1H3/t18-,22+,23-/m0/s1",FJRARMQVERMSNJ-NMNUPHIUSA-N,Agonist,Agonist,,,,,pKi,,9.22,,Ki,,0.6,,=,Displacement of [125I]Ioxycodone from human mu opioid receptor expressed in CHO cells,,,17625813, μ receptor,319,,None,EG-1-203,12732,,155771777,C(CC1=CC=CC=C1)N2[C@H]3CCC[C@@](CC2)([C@H]3CCC)C=4C=C(C=CC4)O,"InChI=1S/C25H33NO/c1-2-8-23-24-13-7-15-25(23,21-11-6-12-22(27)19-21)16-18-26(24)17-14-20-9-4-3-5-10-20/h3-6,9-12,19,23-24,27H,2,7-8,13-18H2,1H3/t23-,24-,25-/m0/s1",GWXQYLLBILOVKW-SDHOMARFSA-N,None,None,,,,,pEC50,,9.02,,EC50,,0.95,,=,"Agonist activity at human MOR, determined in a forskolin-stimulated cAMP accumulation luminescence assay",,,33479684, μ receptor,319,P35372,Human,EG-1-230,12733,,155771774,OC/C=C/[C@H]1[C@H]2N(CC[C@@]1(CCC2)C=3C=C(C=CC3)O)CCC4=CC=CC=C4,"InChI=1S/C25H31NO2/c27-18-6-11-23-24-12-5-14-25(23,21-9-4-10-22(28)19-21)15-17-26(24)16-13-20-7-2-1-3-8-20/h1-4,6-11,19,23-24,27-28H,5,12-18H2/b11-6+/t23-,24-,25-/m0/s1",FTDOOEOFAZGQEK-ZADLEFMZSA-N,Agonist,Agonist,,,,,pKi,,9.22,,Ki,,0.6,,=,Displacement of [125I]Ioxycodone from human mu opioid receptor,,,17625813, μ receptor,319,P35372,Human,isotonitazene,12955,,145721979,CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OC(C)C,"InChI=1S/C23H30N4O3/c1-5-25(6-2)13-14-26-22-12-9-19(27(28)29)16-21(22)24-23(26)15-18-7-10-20(11-8-18)30-17(3)4/h7-12,16-17H,5-6,13-15H2,1-4H3",OIOQREYBGDAYGT-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pEC50,,10.3,,EC50,,0.05,,=,Potency determined in a cAMP accumulation assay in HEK cells expressing hMOR,,,37276825, μ receptor,319,P33535,Rat,isotonitazene,12955,,145721979,CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OC(C)C,"InChI=1S/C23H30N4O3/c1-5-25(6-2)13-14-26-22-12-9-19(27(28)29)16-21(22)24-23(26)15-18-7-10-20(11-8-18)30-17(3)4/h7-12,16-17H,5-6,13-15H2,1-4H3",OIOQREYBGDAYGT-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pKi,,7.95,,Ki,,11.2,,=,Binding affinity in rat brain,,,37276825, μ receptor,319,P35372,Human,brorphine,12956,,145975294,CC(C1=CC=C(C=C1)Br)N2CCC(CC2)N3C4=CC=CC=C4NC3=O,"InChI=1S/C20H22BrN3O/c1-14(15-6-8-16(21)9-7-15)23-12-10-17(11-13-23)24-19-5-3-2-4-18(19)22-20(24)25/h2-9,14,17H,10-13H2,1H3,(H,22,25)",CNOFBGYRMCBVLO-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,8.69,,EC50,,2.06,,=,Potency determined in a cAMP accumulation assay in HEK cells expressing hMOR,,,37276825, μ receptor,319,P35372,Human,brorphine,12956,,145975294,CC(C1=CC=C(C=C1)Br)N2CCC(CC2)N3C4=CC=CC=C4NC3=O,"InChI=1S/C20H22BrN3O/c1-14(15-6-8-16(21)9-7-15)23-12-10-17(11-13-23)24-19-5-3-2-4-18(19)22-20(24)25/h2-9,14,17H,10-13H2,1H3,(H,22,25)",CNOFBGYRMCBVLO-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,8.32,,EC50,,4.8,,=,Potency in a GTPγS binding assay,,,30199635, μ receptor,319,P33535,Rat,brorphine,12956,,145975294,CC(C1=CC=C(C=C1)Br)N2CCC(CC2)N3C4=CC=CC=C4NC3=O,"InChI=1S/C20H22BrN3O/c1-14(15-6-8-16(21)9-7-15)23-12-10-17(11-13-23)24-19-5-3-2-4-18(19)22-20(24)25/h2-9,14,17H,10-13H2,1H3,(H,22,25)",CNOFBGYRMCBVLO-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,7.62,,Ki,,24.2,,=,"Binding affinity for rat brain MOR, determined in a radiologand displacement assay",,,37276825, μ receptor,319,P35372,Human,thebaine,13146,,,CN1CC[C@]23[C@@H]4C(=CC=C2[C@H]1CC5=C3C(=C(C=C5)OC)O4)OC,"InChI=1S/C19H21NO3/c1-20-9-8-19-12-5-7-15(22-3)18(19)23-17-14(21-2)6-4-11(16(17)19)10-13(12)20/h4-7,13,18H,8-10H2,1-3H3/t13-,18+,19+/m1/s1",FQXXSQDCDRQNQE-VMDGZTHMSA-N,Agonist,Partial agonist,,,,,pEC50,,5.25,,EC50,,5600.0,,=,Measuring ligand-indiced activation of Gi signalling in a FRET-based assay,,,17616524, μ receptor,319,P35372,Human,mitragynine,13149,,3034396,CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC,"InChI=1S/C23H30N2O4/c1-5-14-12-25-10-9-15-21-18(7-6-8-20(21)28-3)24-22(15)19(25)11-16(14)17(13-27-2)23(26)29-4/h6-8,13-14,16,19,24H,5,9-12H2,1-4H3/b17-13+/t14-,16+,19+/m1/s1",LELBFTMXCIIKKX-QVRQZEMUSA-N,Agonist,Agonist,,,,,pEC50,,9.3,,EC50,,0.5,,=,Determined as inhibition of forskolin-stimulated cAMP accumulation in HEK293T cells expressing human mu opioid receptor,,,34505767, μ receptor,319,P42866,Mouse,mitragynine,13149,,3034396,CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC,"InChI=1S/C23H30N2O4/c1-5-14-12-25-10-9-15-21-18(7-6-8-20(21)28-3)24-22(15)19(25)11-16(14)17(13-27-2)23(26)29-4/h6-8,13-14,16,19,24H,5,9-12H2,1-4H3/b17-13+/t14-,16+,19+/m1/s1",LELBFTMXCIIKKX-QVRQZEMUSA-N,Agonist,Agonist,,,,,pEC50,,6.69,,EC50,,203.0,,=,Determined as agonist-induced [35S]GTPγS binding in CHO cells expressing mouse mu opioid receptor,,,27556704,